id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-276181-5gh0i394	Eimer, J.	Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study.	2020-07-30		.txt	text/plain	1547	91	46	Conclusions: Treatment of critically ill patients with ARDS due to COVID-19 with tocilizumab was not associated with reduced 30-day all-cause mortality, but shorter duration on ventilatory support as well as shorter overall length of stay in hospital and in ICU. Several small studies from China and Europe have reported promising results of the treatment with tocilizumab in patients with COVID-19, preventing the need for admission to an intensive care unit and improving clinical outcomes (4, 5) . In this retrospective cohort study, the administration of tocilizumab did not reduce all cause mortality but was associated with a shorter time on mechanical ventilation and a shorter length of stay in hospital and in ICU in critically ill patients with ARDS due to COVID-19. In summary, our findings indicate that treatment with tocilizumab of critically ill patients with severe ARDS due to COVID-19 may reduce time on mechanical ventilation and overall length of stay in ICU and in hospital.	./cache/cord-276181-5gh0i394.txt	./txt/cord-276181-5gh0i394.txt